title: Efficacy of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a Staphylococcus aureus strain with reduced susceptibility to vancomycin.
abstract: The objective of this study was to evaluate the in vitro and in vivo efficacies of therapies including fosfomycin against clinical Staphylococcus aureus isolates with reduced susceptibility to vancomycin (hGISA). Time-kill curves were performed over 24 h. Peritonitis in C57BL/6 mice was induced by intraperitoneal inoculation of 10(8) CFU/ml. Four hours later (0 h), therapy was started and the treatment groups were: control (not treated), fosfomycin (100 mg/kg/5 h), vancomycin (60 mg/kg/5 h), imipenem (30 mg/kg/5 h), fosfomycin plus linezolid, fosfomycin plus vancomycin and fosfomycin plus imipenem, receiving subcutaneous therapy over 25 h. Bacterial counts in peritoneal fluid, bacteraemia and mortality rates were determined. In vitro, fosfomycin showed a synergistic effect when combined with the other antimicrobials tested. In the animal model, fosfomycin combinations were effective and significantly reduced the bacteraemia rates achieved in the control, imipenem and vancomycin groups (p < 0.05). The best combination in vivo was fosfomycin plus imipenem. Also, fosfomycin plus linezolid was significantly better than vancomycin alone, reducing the bacterial concentration in the peritoneal fluid. In conclusion, in vitro and in vivo, fosfomycin in combination with linezolid, vancomycin or imipenem exerted a good activity. Fosfomycin plus imipenem was the most active combination, decreasing 3 log CFU/ml, and appears to be a promising combination for clinical practice.
authors.affiliation: Infectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. meniapi@hotmail.com
authors.forename: M E
authors.initials: ME
authors.lastname: Pachón-Ibáñez
authors.forename: S
authors.initials: S
authors.lastname: Ribes
authors.forename: M A
authors.initials: MA
authors.lastname: Domínguez
authors.forename: R
authors.initials: R
authors.lastname: Fernández
authors.forename: F
authors.initials: F
authors.lastname: Tubau
authors.forename: J
authors.initials: J
authors.lastname: Ariza
authors.forename: F
authors.initials: F
authors.lastname: Gudiol
authors.forename: C
authors.initials: C
authors.lastname: Cabellos
mesh_terms: D000081:Acetamides / Q000008:administration & dosage*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001202:Ascitic Fluid / Q000382:microbiology; D016470:Bacteremia / Q000382:microbiology; D058491:Bacterial Load; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D005578:Fosfomycin / Q000008:administration & dosage*; D006801:Humans; D015378:Imipenem / Q000008:administration & dosage*; D000069349:Linezolid; D051379:Mice; D008810:Mice, Inbred C57BL; D008826:Microbial Sensitivity Tests; D023303:Oxazolidinones / Q000008:administration & dosage*; D010538:Peritonitis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology / Q000401:mortality; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage*
chemical_list: D000081:Acetamides; D000900:Anti-Bacterial Agents; D023303:Oxazolidinones; D005578:Fosfomycin; D014640:Vancomycin; D015378:Imipenem; D000069349:Linezolid